In a disease where there aren’t a lot of options, nintedanib reduces FVC rate of decline in SSc-ILD by >40%, independently of SSc subtype, antibody status, MMF exposure, just like it does in IPF. Breathtaking results (so to speak) #EULAR2019 Distler for SENSCIS OP0017 @RheumNow https://t.co/eRsMxc7sdr https://t.co/LyqQf5apfx